Key Points
- To review the physiological actions of angiotensin II in the kidney and examine how selective angiotensin II receptor antagonists illuminate renal function and disease progression.
- Evaluation of experimental pharmacology involving orally active, nonpeptide angiotensin II receptor antagonists lacking agonistic, kinin-inducing, or prostaglandin-inducing properties.
- Analysis of renal hemodynamic, glomerular, and tubular responses mediated by specific receptor subtypes (AT1 and AT2).
- Assessment of mechanism-specific renoprotective outcomes associated with renin-angiotensin system inhibition versus alternative pathways.
- Most renal actions of angiotensin II, including modulation of renal hemodynamics and tubular/glomerular functions, are mediated directly by the AT1 receptor subtype despite the presence of AT2 receptors.
- Angiotensin II plays a major mechanistic role in the progressive deterioration of renal function across chronic kidney diseases.
- The long-term renoprotective benefits of ACE inhibitors are predominantly driven by direct inhibition of the renin-angiotensin system rather than secondary non-angiotensin II mechanisms.
Structured PICO
IInterventionAngiotensin II receptor antagonists
The review clarifies that the renal effects of angiotensin II are primarily mediated by AT1 receptors and that ACE inhibitors protect renal function by inhibiting the renin-angiotensin system.